An pH-responsive liposome for the targeted treatment of Helicobacter pylori

Area of Science:

• Pharmacology
• Nanotechnology
• Microbiology

Background:

• Increasing antibiotic resistance in Helicobacter pylori (H. pylori) necessitates novel therapeutic strategies.
• Luteolin (LUT) exhibits antimicrobial properties but suffers from poor water solubility and suboptimal efficacy.
• Current treatments face challenges including side effects and the development of resistance.

Purpose of the Study:

• To enhance the water solubility and antibacterial efficacy of luteolin (LUT) against H. pylori.
• To develop targeted and acid-responsive nanoparticles for improved H. pylori treatment.
• To evaluate the in vitro and in vivo performance of H-L-NPs compared to existing therapies.

Main Methods:

• Encapsulation of LUT within liposomes.
• Coating liposomes with chitosan quaternary ammonium salts to create H-L-NPs.
• Assessment of solubility, minimum inhibitory concentration (MIC), and in vivo efficacy.
• Evaluation of safety and impact on intestinal microbiota diversity.

Main Results:

• H-L-NPs demonstrated significantly improved solubility and a 1024-fold reduction in MIC compared to LUT.
• H-L-NPs were effective against drug-resistant H. pylori strains.
• In vivo treatment with H-L-NPs showed superior outcomes compared to standard triple therapy.
• H-L-NPs exhibited high safety, specificity, and maintained intestinal microbiota diversity.

Conclusions:

• H-L-NPs represent a significant advancement in anti-H. pylori therapy, overcoming LUT's limitations.
• The targeted, acid-responsive nature of H-L-NPs enhances efficacy and minimizes off-target effects.
• This novel formulation shows potential for preventing H. pylori drug resistance and offers a promising therapeutic lead.